The Covid-19 outbreak, with countless of cases and half a million deaths to date, has brought a massive impact to patients, families, and health professionals. It has also profoundly transformed Pharma, Biotech and MedTech companies, both from an innovation and commercialization perspective. But, as restrictions are progressively lifted in Asia and Europe, will we all go back to business as usual, once the wave has passed, or is the industry going through a massive, irreversi

Shift to digital only and remote interactions was/is the only available option during the pandemic. I expect the new normal to be synchronized omni-channel, built on newly acquired digital fluency, as well as established relationships and trust, both between patients-HCPs and HCPs-Pharma & Medtech field teams. #postcovid19 #newnormal #bluejetconsulting Continue reading

Orthopedic, Cardiac, Neuro surgeons expect 3/4 of elective procedures returning by September, survey says. This should help MedTech companies recover after 40-70% sales decrease in April and May. #postcovid19 #newnormal #bluejetconsulting Continue reading

Following initial surge due to Covid-19, patients continue seeing doctors remotely because it's more convenient and faster than in person. According to UnitedHealth, this trend is here to stay. What now remains to be seen is whether telehealth, when possible, improves the quality and affordability of healthcare #postcovid19 #newnormal #bluejetconsulting Continue reading

Restarting elective procedures ? Medicare/Medicaid has released guidance: - continue preventing the spread of the virus - reduce in-person services with telehealth - advise high risk atients to shelter in place - be ready to respond to a surge in COVID-19 cases, if necessary #postcovid19 #newnormal #bluejetconsulting Continue reading